

# Dao-bin Zhou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3157687/publications.pdf>

Version: 2024-02-01

207  
papers

3,116  
citations

257101

24  
h-index

253896

43  
g-index

245  
all docs

245  
docs citations

245  
times ranked

2963  
citing authors

#	ARTICLE	IF	CITATIONS
1	Histogram Analysis Based on Apparent Diffusion Coefficient Maps of Bone Marrow in Multiple Myeloma: An Independent Predictor for High-risk Patients Classified by the Revised International Staging System. <i>Academic Radiology</i> , 2022, 29, e98-e107.	1.3	2
2	Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial. <i>Circulation</i> , 2022, 145, 8-17.	1.6	25
3	Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study. <i>Age and Ageing</i> , 2022, 51, .	0.7	7
4	Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis. <i>Leukemia</i> , 2022, 36, 573-576.	3.3	24
5	Clinical Significance of Plasma Epstein-Barr Virus DNA in Peripheral T-Cell Lymphomas. <i>Acta Haematologica</i> , 2022, 145, 132-143.	0.7	3
6	Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis. <i>American Journal of Hematology</i> , 2022, 97, 203-208.	2.0	25
7	Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study. <i>Annals of Hematology</i> , 2022, 101, 831-836.	0.8	3
8	Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial. <i>Investigational New Drugs</i> , 2022, 40, 349.	1.2	2
9	A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. <i>Leukemia and Lymphoma</i> , 2022, 63, 618-626.	0.6	13
10	A retrospective study of ultrahigh-risk (Mayo 2004 stage IIIb) AL amyloidosis and identification of predictors related to extremely early death. <i>Leukemia and Lymphoma</i> , 2022, 63, 1758-1761.	0.6	1
11	Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 39.	1.2	1
12	The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. <i>Leukemia</i> , 2022, , .	3.3	0
13	Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis. <i>Leukemia</i> , 2022, , .	3.3	2
14	Case Report: Outcome and Adverse Events of Anti-PD-1 Antibody Plus Chidamide for Relapsed/Refractory SÅ©zary Syndrome: Case Series and A Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, 842123.	1.3	1
15	Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of <scp>CEBPA</scp>. <i>British Journal of Haematology</i> , 2022, 198, .	1.2	1
16	Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature. <i>Annals of Hematology</i> , 2022, , .	0.8	0
17	Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis. <i>Hematology</i> , 2022, 27, 757-764.	0.7	2
18	Two-year follow-up result of RELIANCE study, a multicenter phase 2 trial of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7529-7529.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Adult Langerhans cell histiocytosis with thyroid gland involvement: clinical presentation, genomic analysis, and outcome. <i>Annals of Hematology</i> , 2022, 101, 1925-1929.	0.8	5
20	Langerhans cell histiocytosis in adolescent patients: a single-centre retrospective study. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, .	1.2	4
21	Long-term treatment response to PD-1 blockade therapy in a patient with DLBCL relapsed after anti-CD19 chimeric antigen receptor T cell treatment. <i>Annals of Hematology</i> , 2021, 100, 289-291.	0.8	3
22	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. <i>Leukemia</i> , 2021, 35, 1197-1202.	3.3	9
23	Posttreatment dFLC less than 10â€‰%mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib. <i>Leukemia and Lymphoma</i> , 2021, 62, 874-882.	0.6	12
24	A highly heterogeneous mutational pattern in POEMS syndrome. <i>Leukemia</i> , 2021, 35, 1100-1107.	3.3	17
25	Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma. <i>European Radiology</i> , 2021, 31, 1843-1852.	2.3	19
26	Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms. <i>Hematology</i> , 2021, 26, 460-464.	0.7	7
27	UCD with MCD-like inflammatory state: surgical excision is highly effective. <i>Blood Advances</i> , 2021, 5, 122-128.	2.5	11
28	Long-time remission of laryngeal Rosaiâ€‰Dorfman disease with thalidomide: a report of three cases. <i>Hematology</i> , 2021, 26, 552-555.	0.7	5
29	The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study. <i>Cancer Biology and Medicine</i> , 2021, 18, 841-848.	1.4	15
30	Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma. <i>BMC Cancer</i> , 2021, 21, 183.	1.1	8
31	The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 1251-1260.	0.8	4
32	Revealing serum lipidomic characteristics and potential lipid biomarkers in patients with POEMS syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4307-4315.	1.6	4
33	Circulating tumor DNA by highâ€‰throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1041-1049.	0.7	8
34	Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients. <i>Frontiers in Microbiology</i> , 2021, 12, 646361.	1.5	16
35	Novel model predicts prognosis for patients with diffuse large B-cell lymphoma in first relapse after initial R-CHOP therapy: a single-institution study in China. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110029.	0.4	1
36	Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).. <i>Journal of Clinical Oncology</i> , 2021, 39, 2507-2507.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study. <i>Chinese Medical Journal</i> , 2021, 134, 1299-1309.	0.9	4
38	Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study. <i>Frontiers in Oncology</i> , 2021, 11, 701507.	1.3	7
39	A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL. <i>Frontiers in Oncology</i> , 2021, 11, 682436.	1.3	6
40	Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome. <i>Annals of Hematology</i> , 2021, 100, 2755-2761.	0.8	13
41	A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2021, 27, 5492-5501.	3.2	19
42	Pulmonary manifestations of Erdheim-Chester disease: clinical characteristics, outcomes and comparison with Langerhans cell histiocytosis. <i>British Journal of Haematology</i> , 2021, 194, 1024-1033.	1.2	6
43	Treatment and outcomes of POEMS syndrome: changes in the past 20 years. <i>Blood Cancer Journal</i> , 2021, 11, 145.	2.8	11
44	Extranodal NK/T-Cell Lymphoma Occurring Primarily in the Eyes and with Central Nervous System Relapse. <i>Cancer Management and Research</i> , 2021, Volume 13, 6579-6583.	0.9	1
45	The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. <i>Journal of Hematology and Oncology</i> , 2021, 14, 145.	6.9	124
46	Light-Chain Amyloidosis With Peripheral Neuropathy as an Initial Presentation. <i>Frontiers in Neurology</i> , 2021, 12, 707134.	1.1	3
47	Impact of Physicians' Personalities and Behavioral Traits on Treatment-Related Decision-making for Elderly Acute Myeloid Leukemia. <i>Journal of General Internal Medicine</i> , 2021, 36, 3023-3030.	1.3	7
48	Relmacabtagene autoleucel (relmaacelel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. <i>Cancer Medicine</i> , 2021, 10, 999-1011.	1.3	50
49	Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. <i>Journal of Hematology and Oncology</i> , 2021, 14, 167.	6.9	21
50	Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 757403.	1.3	4
51	A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. <i>Frontiers in Oncology</i> , 2021, 11, 750323.	1.3	12
52	Effective treatment of progressive nodular histiocytosis by intermediate-dose cytarabine: a case report and literature review. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 9040-9047.	0.0	1
53	The Interim Analysis from a Prospective Single-Center Phase 2 Study of Zanubrutinib Plus R-CHOP in Treat-Naïve Intravascular Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 3563-3563.	0.6	2
54	<sup>11</sup> C-acetate positron emission tomography is more precise than <sup>18</sup> F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma. <i>Scientific Reports</i> , 2021, 11, 22188.	1.6	8

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients. <i>Blood</i> , 2021, 138, 46-46.	0.6	8
56	Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 1830-1830.	0.6	6
57	Use of Skin Testing Screening and Desensitization Before the First Exposure of Rituximab. <i>Cancer Management and Research</i> , 2021, Volume 13, 9319-9328.	0.9	0
58	Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series. <i>Frontiers in Oncology</i> , 2021, 11, 760405.	1.3	24
59	A Case of Reversible Cerebral Vasoconstriction Syndrome Triggered by High-Dose Methotrexate in a Boy With Lymphoma. <i>Headache</i> , 2020, 60, 1767-1772.	1.8	5
60	Successful treatment of central nervous system involved Erdheim-Chester disease by intermediate-dose cytarabine as first-line therapy. <i>Acta Oncologica</i> , 2020, 59, 302-305.	0.8	8
61	Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 36-44.	1.4	10
62	Intravenous methotrexate at a dose of 1 g/m <sup>2</sup> incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: A prospective, historic controlled study. <i>American Journal of Hematology</i> , 2020, 95, E80-E83.	2.0	7
63	Prognostic value of interim 18F-FDG PET/CT in T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 927-933.	0.6	3
64	Serum interleukin-10 as a valuable biomarker for early diagnosis and therapeutic monitoring in intravascular large B-cell lymphoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e131.	1.7	0
65	Rituximab-containing therapy for cold agglutinin disease: a retrospective study of 16 patients. <i>Scientific Reports</i> , 2020, 10, 12694.	1.6	7
66	Ischemic stroke in patients with POEMS syndrome. <i>Blood Advances</i> , 2020, 4, 3427-3434.	2.5	11
67	ETV6-ACSL6 fusion gene in myeloid neoplasms: clinical spectrum, current practice, and outcomes. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 192.	1.2	5
68	Central nervous system involvement at diagnosis in extranodal natural killer/T-cell lymphoma: a single-center study. <i>Leukemia and Lymphoma</i> , 2020, 61, 3272-3274.	0.6	2
69	Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma. <i>Medicine (United States)</i> , 2020, 99, e22788.	0.4	4
70	Bone mineral density and bone microarchitecture in a cohort of patients with Erdheim-Chester Disease. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 236.	1.2	2
71	A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma presenting with extensive skin involvements and the results of genetic study. <i>Medicine (United States)</i> , 2020, 99, e21948.	0.4	1
72	Endocrine Evaluation in POEMS Syndrome: A Cohort Study. <i>Frontiers in Endocrinology</i> , 2020, 11, 536241.	1.5	5

#	ARTICLE	IF	CITATIONS
73	Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. <i>Journal of Hematology and Oncology</i> , 2020, 13, 52.	6.9	13
74	Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study. <i>Annals of Hematology</i> , 2020, 99, 2801-2809.	0.8	4
75	Predicting worse survival for newly diagnosed T cell lymphoma based on the decreased baseline CD16 <sup>hi</sup> /CD16 <sup>lo</sup> monocyte ratio. <i>Scientific Reports</i> , 2020, 10, 7757.	1.6	12
76	The combination of methotrexate and cytosine arabinoside in newly diagnosed adult Langerhans cell histiocytosis: a prospective phase II interventional clinical trial. <i>BMC Cancer</i> , 2020, 20, 433.	1.1	2
77	Reliability of optic disc edema area in estimating the severity of papilledema in patients with POEMS syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 116.	1.2	2
78	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 48.	6.9	83
79	Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: A single arm, single center, prospective phase 2 study. <i>American Journal of Hematology</i> , 2020, 95, E235-E238.	2.0	22
80	Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients. <i>Annals of Hematology</i> , 2020, 99, 1735-1740.	0.8	13
81	Prevalence of monoclonal gammopathy of undetermined significance in a large population with annual medical check-ups in China. <i>Blood Cancer Journal</i> , 2020, 10, 34.	2.8	9
82	Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia. <i>Annals of Hematology</i> , 2020, 99, 1141-1143.	0.8	7
83	Detection of the MYD88L265P and CXCR4S338X mutations by cell-free DNA in Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2020, 99, 1763-1769.	0.8	11
84	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. <i>Thoracic Cancer</i> , 2020, 11, 799-804.	0.8	24
85	Successful treatment of intracranial Rosai-Dorfman disease with cytarabine and dexamethasone: case report and review of literature. <i>Annals of Hematology</i> , 2020, 99, 1157-1159.	0.8	6
86	Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 597472.	1.1	3
87	An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 29-30.	0.6	17
88	Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies. <i>Blood</i> , 2020, 136, 43-43.	0.6	11
89	Clinical presentation and prognostic analysis of adult patients with Langerhans cell histiocytosis with pulmonary involvement. <i>BMC Cancer</i> , 2020, 20, 911.	1.1	5
90	Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial. <i>Blood</i> , 2020, 136, 42-43.	0.6	3

#	ARTICLE	IF	CITATIONS
91	A Highly Heterogeneous Mutational Pattern in POEMS Syndrome. <i>Blood</i> , 2020, 136, 19-19.	0.6	0
92	Treatment Outcome and Prognostic Factors for Adult Langerhans Cell Histiocytosis. <i>Blood</i> , 2020, 136, 38-38.	0.6	0
93	Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies. <i>Blood</i> , 2020, 136, 36-37.	0.6	0
94	Impact of Hematologists' Personality and Behavioral Traits on Medical Decision-Making for Elderly Acute Myeloid Leukemia: A National Study in China. <i>Blood</i> , 2020, 136, 19-19.	0.6	1
95	Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China. <i>Blood</i> , 2020, 136, 39-40.	0.6	2
96	Unicentric Castleman Disease with High Inflammatory State: Surgical Treatment Is a Potential Cure. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
97	A Prospective, Multicenter Study of Bortezomib, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Idiopathic Multicentric Castleman's Disease. <i>Blood</i> , 2020, 136, 42-42.	0.6	1
98	Evaluating heart function in patients with POEMS syndrome. <i>Echocardiography</i> , 2019, 36, 1997-2003.	0.3	3
99	Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 255-256.	1.4	7
100	Clinical characteristics and prognostic factors in Chinese patients with classical Hodgkin's lymphoma involving extranodal sites: a retrospective single-center study. <i>Hematology</i> , 2019, 24, 661-668.	0.7	1
101	Clinical presentation and prognostic analysis of Chinese patients with systemic light chain amyloidosis with liver involvement. <i>Leukemia Research</i> , 2019, 86, 106226.	0.4	8
102	What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?. <i>Leukemia</i> , 2019, 33, 1023-1029.	3.3	43
103	Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone. <i>Hematology</i> , 2019, 24, 516-520.	0.7	7
104	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) associated with or without lymphoma: Comparison of clinical features and risk factors suggestive of underlying lymphomas. <i>Journal of Clinical Neuroscience</i> , 2019, 66, 156-164.	0.8	10
105	Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 66-73.	1.4	17
106	The role of high serum CXCL13 level in Waldenström macroglobulinemia. <i>Leukemia Research</i> , 2019, 81, 50-55.	0.4	1
107	Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis. <i>Hematology</i> , 2019, 24, 392-398.	0.7	29
108	Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide, vincristine, and prednisone. <i>Journal of International Medical Research</i> , 2019, 47, 1810-1814.	0.4	1

#	ARTICLE	IF	CITATIONS
109	Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells. <i>Cancer Medicine</i> , 2019, 8, 2104-2113.	1.3	14
110	Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells. <i>Leukemia Research</i> , 2019, 81, 19-24.	0.4	5
111	Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy—A Single-Center Cohort Study of 227 Patients. <i>Circulation Journal</i> , 2019, 83, 775-782.	0.7	8
112	Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. <i>Blood</i> , 2019, 133, 1720-1728.	0.6	45
113	Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib. <i>Chinese Medical Journal</i> , 2019, 132, 2002-2003.	0.9	2
114	Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China. <i>Annals of Hematology</i> , 2019, 98, 143-150.	0.8	6
115	Improvement of thyroid function in POEMS syndrome after combination therapy of lenalidomide and dexamethasone. <i>Leukemia and Lymphoma</i> , 2019, 60, 483-487.	0.6	4
116	Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy. <i>Annals of Hematology</i> , 2019, 98, 735-743.	0.8	11
117	Clinical and positron emission tomography responses to long-term high-dose interferon- $\gamma$ treatment among patients with Erdheim-Chester disease. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 11.	1.2	17
118	Autoimmune disease-associated non-Hodgkin's lymphoma—a large retrospective study from China. <i>Annals of Hematology</i> , 2019, 98, 445-455.	0.8	13
119	Bortezomib-based chemotherapy can improve renal and tubular functions in patients with light chain-associated Fanconi syndrome. <i>Annals of Hematology</i> , 2019, 98, 1095-1100.	0.8	10
120	Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial. <i>Blood</i> , 2019, 134, 4036-4036.	0.6	4
121	Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study. <i>Blood</i> , 2019, 134, 1870-1870.	0.6	3
122	Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China. <i>Blood</i> , 2019, 134, 2127-2127.	0.6	6
123	Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study. <i>Blood</i> , 2019, 134, 294-294.	0.6	1
124	Characteristics of Serum Lipidome in Patients with POEMS Syndrome. <i>Blood</i> , 2019, 134, 3082-3082.	0.6	0
125	Prevalence of Monoclonal Gammopathy of Undetermined Significance in a Large Population with Annual Physical Examination in Beijing, China. <i>Blood</i> , 2019, 134, 5519-5519.	0.6	0
126	Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study. <i>Blood</i> , 2019, 134, 5493-5493.	0.6	1

#	ARTICLE	IF	CITATIONS
127	ALK+ small cell variant of anaplastic large cell lymphoma with leukemic presentation. <i>Blood</i> , 2018, 131, 1764-1764.	0.6	3
128	Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome. <i>Blood Cancer Journal</i> , 2018, 8, 37.	2.8	22
129	Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. <i>Cancer Medicine</i> , 2018, 7, 1043-1055.	1.3	32
130	Successful Treatment of Type 1 Cryoglobulinemic Vasculitis With Cardiac Involvement. <i>Canadian Journal of Cardiology</i> , 2018, 34, 343.e1-343.e3.	0.8	5
131	Comparative study of porcine anti-human lymphocyte immunoglobulin and rabbit anti-human thymocyte immunoglobulin as a first-line treatment of acquired severe aplastic anemia. <i>Leukemia Research</i> , 2018, 65, 55-60.	0.4	17
132	Plerixafor and granulocyte colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study. <i>Transfusion</i> , 2018, 58, 81-87.	0.8	21
133	The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology. <i>Journal of Hematology and Oncology</i> , 2018, 11, 33.	6.9	233
134	A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. <i>American Journal of Hematology</i> , 2018, 93, 803-809.	2.0	49
135	Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease. <i>Annals of Hematology</i> , 2018, 97, 185-187.	0.8	9
136	TAFRO Syndrome – A Specific Subtype of Castleman's Disease in China. <i>Chinese Medical Journal</i> , 2018, 131, 1868-1870.	0.9	5
137	Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients. <i>Cancer Cell International</i> , 2018, 18, 215.	1.8	19
138	Successful Treatment of Erdheim-Chester Disease With Coronary Artery Involvement. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1688.e9-1688.e11.	0.8	3
139	Impact of lenalidomide exposure on blood cell collection for autotransplants in persons with POEMS syndrome. <i>Archives of Medical Science</i> , 2018, 14, 1048-1054.	0.4	1
140	Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma. <i>Leukemia Research</i> , 2018, 70, 56-61.	0.4	9
141	Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients. <i>Oncology Letters</i> , 2018, 16, 1602-1614.	0.8	22
142	Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. <i>Annals of Hematology</i> , 2018, 97, 1641-1647.	0.8	26
143	The optimal timing of radiotherapy in the combined modality therapy for limited-stage extranodal NK/T cell lymphoma (ENKTL): a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2018, 97, 2279-2287.	0.8	11
144	Survival Comparison of Three Treatment Regimens of POEMS Syndrome: A Single-Center Retrospective Study. <i>Blood</i> , 2018, 132, 3428-3428.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Bortezomib-Based Chemotherapy Reduces Early Mortality and Improves Outcomes in Patients with Ultra-High-Risk Light-Chain Amyloidosis. <i>Blood</i> , 2018, 132, 3304-3304.	0.6	0
146	Outcome of anti-thymocyte immunoglobulin plus cyclosporine A for severe aplastic anaemia with chronic hepatitis B virus infection. <i>Annals of Hematology</i> , 2017, 96, 581-587.	0.8	3
147	Successful treatment of refractory Sezary syndrome by anti-PD-1 antibody (nivolumab). <i>Annals of Hematology</i> , 2017, 96, 687-688.	0.8	11
148	Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 360-367.	0.8	18
149	Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. <i>Annals of Hematology</i> , 2017, 96, 971-976.	0.8	26
150	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 69.	6.9	155
151	At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment. <i>Annals of Hematology</i> , 2017, 96, 2089-2094.	0.8	15
152	Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations. <i>Annals of Hematology</i> , 2017, 96, 1867-1871.	0.8	29
153	Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese. <i>Scientific Reports</i> , 2017, 7, 17053.	1.6	10
154	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 137.	6.9	56
155	Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 47790-47800.	0.8	11
156	Clinical Analysis of Unicentric Castleman's Disease with Paraneoplastic Pemphigus and Bronchiolitis Obliterans. <i>Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae</i> , 2017, 39, 492-498.	0.2	5
157	Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: incidence, treatment and outcome. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, gfv261.	0.4	23
158	Acute promyelocytic leukaemia with promyelocyte count below 20%. <i>British Journal of Haematology</i> , 2016, 173, 11-11.	1.2	0
159	Successful treatment of scleromyxedema with melphalan and dexamethasone followed by thalidomide maintenance therapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 2934-2936.	0.6	10
160	Long-term follow-up study of porcine anti-human thymocyte immunoglobulin therapy combined with cyclosporine for severe aplastic anemia. <i>European Journal of Haematology</i> , 2016, 96, 291-296.	1.1	32
161	Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia. <i>Clinical Transplantation</i> , 2016, 30, 263-269.	0.8	6
162	Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman's disease: renal function is an important prognostic factor. <i>Scientific Reports</i> , 2016, 6, 23831.	1.6	24

#	ARTICLE	IF	CITATIONS
163	Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma. <i>Scientific Reports</i> , 2016, 6, 38671.	1.6	67
164	The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients. <i>Leukemia Research</i> , 2016, 46, 85-88.	0.4	20
165	Remarkable expression of vascular endothelial growth factor in bone marrow plasma cells of patients with POEMS syndrome. <i>Leukemia Research</i> , 2016, 50, 78-84.	0.4	36
166	PD-1 expression on the surface of peripheral blood CD4 + T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2016, 5, 3077-3084.	1.3	26
167	Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population. <i>Frontiers of Medicine</i> , 2016, 10, 437-443.	1.5	2
168	Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. <i>BMC Cancer</i> , 2016, 16, 46.	1.1	1
169	Improvement of sexual function in POEMS syndrome after combination therapy of Lenalidomide and dexamethasone. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 80.	1.2	7
170	Prognostic value of serum heavy/light chain ratios in patients with <sc>POEMS</sc> syndrome. <i>European Journal of Haematology</i> , 2016, 97, 48-54.	1.1	9
171	Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. <i>Annals of Hematology</i> , 2016, 95, 745-750.	0.8	26
172	Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China. <i>Tumor Biology</i> , 2016, 37, 7893-7900.	0.8	10
173	Bone lesions in Chinese POEMS syndrome patients: imaging characteristics and clinical implications. <i>PeerJ</i> , 2016, 4, e2294.	0.9	7
174	Peritransplant Complications and Long-Term Outcomes of Patients with Newly Diagnosed POEMS Syndrome after Upfront Autologous Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2259-2259.	0.6	0
175	A successful case of second autologous haematopoietic stem cell transplantation for post-transplant systemic sclerosis relapse. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 207.	0.4	1
176	Clinical Features of Patients with Castleman's Disease Complicated Systemic Lupus Erythematosus. <i>Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae</i> , 2016, 38, 543-547.	0.2	4
177	Selection of Biopsy Site for Patients with Systematic Amyloidosis. <i>Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae</i> , 2016, 38, 706-709.	0.2	1
178	Diagnosis of <i>Penicillium marneffeii</i> infection from a blood film. <i>British Journal of Haematology</i> , 2015, 171, 670-670.	1.2	3
179	Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory <sc>POEMS</sc> syndrome. <i>European Journal of Haematology</i> , 2015, 95, 325-330.	1.1	38
180	The Successful Diagnosis and Typing of Systemic Amyloidosis Using A Microwave-Assisted Filter-Aided Fast Sample Preparation Method and LC/MS/MS Analysis. <i>PLoS ONE</i> , 2015, 10, e0127180.	1.1	14

#	ARTICLE	IF	CITATIONS
181	Comparison of Different Buffers for Protein Extraction from Formalin-Fixed and Paraffin-Embedded Tissue Specimens. <i>PLoS ONE</i> , 2015, 10, e0142650.	1.1	27
182	Characterizing POEMS Syndrome with 18F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1334-1337.	2.8	36
183	Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment. <i>International Journal of Hematology</i> , 2015, 101, 569-577.	0.7	9
184	Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: A multicenter prospective study of 2302 patients in China. <i>Leukemia Research</i> , 2015, 39, 530-535.	0.4	15
185	A Paracrine Circuit Regulates Vascular Endothelial Growth Factor Production By Bone Marrow Plasma Cells in Patients with POEMS Syndrome. <i>Blood</i> , 2015, 126, 1757-1757.	0.6	0
186	Interim Results of a Multi-Center Observational Study of Current Treatment Patterns for Patients with Severe Aplastic Anemia (SAA), Very Severe Aplastic Anemia (VSAA) and Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) in China. <i>Blood</i> , 2015, 126, 4505-4505.	0.6	0
187	Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. <i>Leukemia Research</i> , 2014, 38, 188-193.	0.4	16
188	Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse. <i>Annals of Hematology</i> , 2014, 93, 1001-1005.	0.8	18
189	Markedly elevated serum total N-terminal propeptide of type I collagen is a novel marker for the diagnosis and follow up of patients with POEMS syndrome. <i>Haematologica</i> , 2014, 99, e78-e80.	1.7	33
190	Risk of Multiple Myeloma in Rheumatoid Arthritis: A Meta-Analysis of Case-Control and Cohort Studies. <i>PLoS ONE</i> , 2014, 9, e91461.	1.1	18
191	Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP). <i>Blood</i> , 2014, 124, 5737-5737.	0.6	0
192	A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. <i>Journal of Hematology and Oncology</i> , 2013, 6, 41.	6.9	41
193	New advances in the diagnosis and treatment of <sc>POEMS</sc> syndrome. <i>British Journal of Haematology</i> , 2013, 161, 303-315.	1.2	75
194	14q32 translocations and 13q14 deletions are common cytogenetic abnormalities in <sc>POEMS</sc> syndrome. <i>European Journal of Haematology</i> , 2013, 91, 490-496.	1.1	18
195	Pulmonary hypertension in POEMS syndrome. <i>Haematologica</i> , 2013, 98, 393-398.	1.7	55
196	A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Postâ€“Polycythemia Vera MF (PPV-MF), Or Postâ€“Essential Thrombocythemia MF (ET-MF). <i>Blood</i> , 2013, 122, 4086-4086.	0.6	12
197	The MM-021 Trial Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma: Impact Of Prior Therapies On Efficacy and Safety. <i>Blood</i> , 2013, 122, 3227-3227.	0.6	0
198	Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure. <i>Leukemia and Lymphoma</i> , 2012, 53, 2527-2529.	0.6	15

#	ARTICLE	IF	CITATIONS
199	Characterization of immunoglobulin $\lambda$ light chain variable region (IGLV) gene and its relationship with clinical features in patients with POEMS syndrome. <i>Annals of Hematology</i> , 2012, 91, 1251-1255.	0.8	15
200	Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial. <i>Blood</i> , 2012, 120, 5046-5046.	0.6	0
201	A Multi-Center, Open-Label Phase II Study of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma - the MM-021 Trial. <i>Blood</i> , 2012, 120, 1864-1864.	0.6	0
202	The Interaction Between Stromal Cell-Derived Factor 1 Alpha (SDF-1 $\alpha$ ) and Dickkopf-1 (DKK-1) Mediates Myeloma Bone Disease. <i>Blood</i> , 2012, 120, 1824-1824.	0.6	0
203	Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. <i>Blood</i> , 2011, 117, 6445-6449.	0.6	174
204	Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. <i>Annals of Hematology</i> , 2011, 90, 819-826.	0.8	117
205	Telomerase Gene Screening and Telomere Overhang Detection in Chinese Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 1467-1467.	0.6	0
206	An open-label study of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients in the Chinese population. <i>Clinical Oncology and Cancer Research</i> , 2009, 6, 394-400.	0.1	0
207	Treatment of Primary Central Nervous System Lymphoma with a Combination of Intraventricular Administration of Rituximab and Systemic Chemotherapy. <i>Blood</i> , 2006, 108, 4695-4695.	0.6	0